Quality & innovation
Learn about our quality & innovation
Science designed to improve lives
Advancing science where it matters most
Established as a standalone business in 2020, Merz Therapeutics is a global specialty pharmaceutical company focused on addressing unmet needs in neurology, including movement disorders and other serious conditions that can significantly affect quality of life.
Building on a long legacy of innovation within the Merz Group and working closely with partners across the United States, we prioritize the development and delivery of medicines designed to support patients in managing the symptoms that most impact their daily lives.
Explore our pipeline
We are developing innovative medicines to improve patient outcomes, and exploring new clinical settings for our existing portfolio. Our pipeline is focused on specialty neurology, where we are best-placed to make the most difference.
A proud innovator in therapeutic innovation and delivery
In 2024-2025 we:
Led 19 hands-on medical education courses
Trained 350 HCPs
Advanced scientific engagement through 31 abstracts/posters and 6 accepted manuscripts
Translating science into treatment
Our specialization in neurology has led to a portfolio of licensed medicines designed to support patients across a range of complex conditions.
Each product in our portfolio reflects the careful translation of scientific insight into regulated therapies, developed and manufactured to meet rigorous quality and safety standards in the United States.
To learn more about individual medicines, including prescribing information and instructions for use, please visit our Products page.
Supporting independent research
Merz Therapeutics is a proud supporter of Investigator Initiated Trials (IITs). IITs are clinical research studies conducted by independent investigators – usually physicians or researchers. They often focus on a clinical theory or research topic where existing evidence is incomplete or lacking.
Supporting IITs is part of our commitment to innovation in specialty neurology care. The more avenues we can explore, the better the outcomes for patients will be.
